{"protocolSection":{"identificationModule":{"nctId":"NCT00948675","orgStudyIdInfo":{"id":"13258"},"secondaryIdInfos":[{"id":"H3E-US-S130","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"Study of Participants With Advanced Non-Small Cell Lung Cancer","officialTitle":"A Study of Pemetrexed Plus Carboplatin Followed by Maintenance Pemetrexed vs Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Advanced NCSLC of Nonsquamous Histology"},"statusModule":{"statusVerifiedDate":"2021-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-09-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2013-01-31","type":"ACTUAL"},"completionDateStruct":{"date":"2020-11-06","type":"ACTUAL"},"studyFirstSubmitDate":"2009-07-28","studyFirstSubmitQcDate":"2009-07-28","studyFirstPostDateStruct":{"date":"2009-07-29","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-01-14","resultsFirstSubmitQcDate":"2014-03-04","resultsFirstPostDateStruct":{"date":"2014-04-02","type":"ESTIMATED"},"lastUpdateSubmitDate":"2021-10-18","lastUpdatePostDateStruct":{"date":"2021-10-29","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to compare the regimens of pemetrexed, carboplatin with pemetrexed maintenance and paclitaxel, carboplatin, bevacizumab with bevacizumab maintenance in participants with Stage IV nonsquamous non-small cell lung cancer.","detailedDescription":"This is a multicenter, randomized, open-label, Phase III trial. Eligible participants will be randomized in a 1:1 ratio to receive pemetrexed and carboplatin followed by pemetrexed or paclitaxel, carboplatin, and bevacizumab followed by bevacizumab as their study treatment. Participants randomized to Pemetrexed + Carboplatin + Pemetrexed will receive folic acid, vitamin B12, and dexamethasone as stated in the pemetrexed label. Before administration of paclitaxel, participants randomized to Paclitaxel + Carboplatin + Bevacizumab will receive premedication (dexamethasone, diphenhydramine, and cimetidine or ranitidine) as recommended in the paclitaxel label."},"conditionsModule":{"conditions":["Advanced Non-Small Cell Lung Cancer"],"keywords":["Advanced Non-Small Cell Lung Cancer of Nonsquamous Histology","Advanced Lung Cancer","Non-Small Cell Lung Cancer","Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":361,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Pemetrexed + Carboplatin + Pemetrexed","type":"EXPERIMENTAL","description":"Pemetrexed and Carboplatin followed by Pemetrexed","interventionNames":["Drug: Pemetrexed","Drug: Carboplatin"]},{"label":"Paclitaxel + Carboplatin + Bevacizumab","type":"ACTIVE_COMPARATOR","description":"Paclitaxel, Carboplatin, and Bevacizumab followed by Bevacizumab","interventionNames":["Drug: Carboplatin","Drug: Paclitaxel","Biological: Bevacizumab"]}],"interventions":[{"type":"DRUG","name":"Pemetrexed","description":"Induction therapy: 500 milligrams/square meter (mg/m²) given intravenously every 21 days for 4 cycles. Maintenance therapy: 500 mg/m² given intravenously every 21 days until disease progression or treatment discontinuation.","armGroupLabels":["Pemetrexed + Carboplatin + Pemetrexed"],"otherNames":["ALIMTA, LY231514"]},{"type":"DRUG","name":"Carboplatin","description":"Induction Therapy (every 21 days for 4 cycles): Area Under the Curve (AUC) 6 \\[maximum possible dose of 900 milligrams (mg)\\] intravenously infused over 30 minutes.","armGroupLabels":["Paclitaxel + Carboplatin + Bevacizumab","Pemetrexed + Carboplatin + Pemetrexed"]},{"type":"DRUG","name":"Paclitaxel","description":"Induction Therapy (every 21 days for 4 cycles): 200 mg/m² intravenously infused over 3 hours","armGroupLabels":["Paclitaxel + Carboplatin + Bevacizumab"]},{"type":"BIOLOGICAL","name":"Bevacizumab","description":"Induction therapy: 15 milligrams/kilogram (mg/kg) given intravenously every 21 days for 4 cycles. Maintenance therapy: 15 mg/kg given intravenously every 21 days until disease progression or treatment discontinuation.","armGroupLabels":["Paclitaxel + Carboplatin + Bevacizumab"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression Free Survival Without Grade 4 Toxicity (G4PFS) as Measured by the Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0","description":"G4PFS was defined as the duration from the date of randomization to the earliest occurrence date of one of the following three events: Common Terminology Criteria (CTC) grade 4 adverse events (G4AEs), or progressive disease (PD) or death from any cause, whichever occurred earlier. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. PD is ≥20% increase in sum of longest diameter of target lesions or the appearance of new lesions. For participants who had no G4AEs, or PD, or death at the time of the data inclusion cutoff, PFS was censored at their last objective progression-free disease assessment prior to the cutoff date or the date of initiation of subsequent systemic anticancer therapy.","timeFrame":"Randomization to measured progressive disease or treatment discontinuation up to 39.49 months"}],"secondaryOutcomes":[{"measure":"Progression Free Survival (PFS)","description":"PFS was defined as the duration from the date of randomization to the date of progressive disease (PD) or death from any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. PD was ≥20% increase in sum of longest diameter of target lesions or the appearance of new lesions. For participants who had no PD or death at the time of the data inclusion cutoff, PFS was censored at their last objective progression-free disease assessment prior to the cutoff date or the date of initiation of subsequent systemic anticancer therapy.","timeFrame":"Randomization to measured progressive disease up to 39.49 months"},{"measure":"Overall Survival (OS)","description":"OS was defined as the duration from the date of randomization to the date of death from any cause. For participants who were alive at the time of the data inclusion cutoff, OS was censored at the last date the participant was known to be alive.","timeFrame":"Randomization to date of death from any cause up to 39.49 months"},{"measure":"Percentage of Participants With Complete Response or Partial Response (Overall Tumor Response Rate)","description":"Overall Response rate (ORR) was the percentage of participants with a confirmed complete response (CR) or partial response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. CR was the disappearance of all target and non-target lesions; PR was a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesions. ORR was calculated as a total number of participants with CR or PR from the start of study treatment until disease progression or recurrence divided by the total number of participants treated, then multiplied by 100.","timeFrame":"Baseline to date of objective progressive disease up to 39.49 months"},{"measure":"Disease Control Rates Defined as Complete Response (CR), Partial Response (PR), and Stable Disease (SD)","description":"Disease control rate was the percentage of participants with a confirmed CR, PR or SD, as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. CR was the disappearance of all target and non-target lesions; PR was a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesion; SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Disease control rate was calculated as a total number of participants with CR or PR or SD divided by the total number of participants treated, then multiplied by 100.","timeFrame":"Baseline to date of objective progressive disease up to 39.49 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* a histologic or cytologic diagnosis of advanced non-small cell lung cancer (NSCLC) \\[Stage IV from the American Joint Committee on Cancer Staging Criteria (AJCC) staging system, version 7.0, including both M1a and M1b\\], other than predominantly squamous cell histology, that is not amenable to curative therapy. Participants may not have received any prior systemic chemotherapy, immunotherapy, targeted therapy, or biological therapy, including adjuvant therapy, for any stage of NSCLC.\n* prior radiation therapy is allowed to \\< 25% of the bone marrow; however, prior radiation to the whole pelvis not allowed.\n* good performance status.\n* adequate organ function.\n* estimated life expectancy of at least 12 weeks.\n\nExclusion Criteria:\n\n* known central nervous system (CNS) disease, other than treated brain metastasis.\n* major surgical procedure, open biopsy, open pleurodesis, or significant traumatic injury within 28 days prior to study or have an anticipated need for major surgery during the study.\n* core biopsy or other minor surgical procedure, excluding placement of vascular access device, closed pleurodesis, thoracentesis, and mediastinoscopy, within 7 days prior to study.\n* history of gastrointestinal fistula, perforation, or abscess, inflammatory bowel disease, or diverticulitis.\n* currently receiving ongoing treatment with full-dose warfarin or equivalent\n* significant vascular disease within 6 months prior to Day 1 of Cycle 1.\n* evidence of bleeding diathesis or coagulopathy.\n* serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the participant's ability to adhere to the protocol.\n* serious cardiac condition, such as myocardial infarction, angina, or heart disease.\n* inadequately controlled hypertension.\n* any prior history of hypertensive crisis or hypertensive encephalopathy.\n* serious, nonhealing wound, active ulcer, or untreated bone fracture.\n* another active malignancy, other than superficial basal cell and superficial squamous (skin) cell, or carcinoma in situ of the cervix within the last 5 years.\n* previously received treatment with paclitaxel, carboplatin, pemetrexed, or bevacizumab (prior intravitreal administration of bevacizumab does not preclude study participation).\n* pregnant or breast-feeding.\n* history of stroke or transient ischemic attack within 6 months prior to study.\n* known sensitivity to any component of paclitaxel, carboplatin, pemetrexed, or bevacizumab.\n* history of hemoptysis within 3 months prior to randomization.\n* unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs).\n* unwilling to take folic acid or vitamin B12 supplementation.\n* clinically significant third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage. Participants with M1a disease with pleural effusions are eligible if the effusions can be adequately controlled.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Scottsdale","state":"Arizona","zip":"85259","country":"United States","geoPoint":{"lat":33.50921,"lon":-111.89903}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tucson","state":"Arizona","zip":"85715","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mission Hills","state":"California","zip":"91345","country":"United States","geoPoint":{"lat":34.68609,"lon":-120.43683}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Aventura","state":"Florida","zip":"33180","country":"United States","geoPoint":{"lat":25.95648,"lon":-80.13921}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Daytona Beach","state":"Florida","zip":"32114","country":"United States","geoPoint":{"lat":29.21081,"lon":-81.02283}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fort Myers","state":"Florida","zip":"33916","country":"United States","geoPoint":{"lat":26.62168,"lon":-81.84059}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Gainesville","state":"Florida","zip":"32610","country":"United States","geoPoint":{"lat":29.65163,"lon":-82.32483}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Jacksonville","state":"Florida","zip":"32256","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Port Saint Lucie","state":"Florida","zip":"34952","country":"United States","geoPoint":{"lat":27.29393,"lon":-80.35033}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Athens","state":"Georgia","zip":"30607","country":"United States","geoPoint":{"lat":33.96095,"lon":-83.37794}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Augusta","state":"Georgia","zip":"30901","country":"United States","geoPoint":{"lat":33.47097,"lon":-81.97484}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Macon","state":"Georgia","zip":"31201","country":"United States","geoPoint":{"lat":32.84069,"lon":-83.6324}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Marietta","state":"Georgia","zip":"30060","country":"United States","geoPoint":{"lat":33.9526,"lon":-84.54993}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Post Falls","state":"Idaho","zip":"83854","country":"United States","geoPoint":{"lat":47.71796,"lon":-116.95159}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Gurnee","state":"Illinois","zip":"60031","country":"United States","geoPoint":{"lat":42.3703,"lon":-87.90202}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Joliet","state":"Illinois","zip":"60435","country":"United States","geoPoint":{"lat":41.52519,"lon":-88.0834}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Goshen","state":"Indiana","zip":"46526","country":"United States","geoPoint":{"lat":41.58227,"lon":-85.83444}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"New Albany","state":"Indiana","zip":"47150","country":"United States","geoPoint":{"lat":38.28562,"lon":-85.82413}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Sioux City","state":"Iowa","zip":"51101","country":"United States","geoPoint":{"lat":42.49999,"lon":-96.40031}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mount Sterling","state":"Kentucky","zip":"40353","country":"United States","geoPoint":{"lat":38.05647,"lon":-83.94326}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ann Arbor","state":"Michigan","zip":"48106","country":"United States","geoPoint":{"lat":42.27756,"lon":-83.74088}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lansing","state":"Michigan","zip":"48910","country":"United States","geoPoint":{"lat":42.73253,"lon":-84.55553}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Southfield","state":"Michigan","zip":"48075","country":"United States","geoPoint":{"lat":42.47337,"lon":-83.22187}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Rochester","state":"Minnesota","zip":"55905","country":"United States","geoPoint":{"lat":44.02163,"lon":-92.4699}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Branson","state":"Missouri","zip":"65616","country":"United States","geoPoint":{"lat":36.64367,"lon":-93.21851}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Billings","state":"Montana","zip":"59107","country":"United States","geoPoint":{"lat":45.78329,"lon":-108.50069}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Great Falls","state":"Montana","zip":"59405","country":"United States","geoPoint":{"lat":47.50024,"lon":-111.30081}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Albuquerque","state":"New Mexico","zip":"87106","country":"United States","geoPoint":{"lat":35.08449,"lon":-106.65114}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Burlington","state":"North Carolina","zip":"27215","country":"United States","geoPoint":{"lat":36.09569,"lon":-79.4378}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"High Point","state":"North Carolina","zip":"27262","country":"United States","geoPoint":{"lat":35.95569,"lon":-80.00532}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bismarck","state":"North Dakota","zip":"58501","country":"United States","geoPoint":{"lat":46.80833,"lon":-100.78374}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fargo","state":"North Dakota","zip":"58122","country":"United States","geoPoint":{"lat":46.87719,"lon":-96.7898}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cincinnati","state":"Ohio","zip":"45242","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tulsa","state":"Oklahoma","zip":"74136","country":"United States","geoPoint":{"lat":36.15398,"lon":-95.99277}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"DuBois","state":"Pennsylvania","zip":"15801","country":"United States","geoPoint":{"lat":41.11923,"lon":-78.76003}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Philadelphia","state":"Pennsylvania","zip":"19107","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Columbia","state":"South Carolina","zip":"29210","country":"United States","geoPoint":{"lat":34.00071,"lon":-81.03481}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Chattanooga","state":"Tennessee","zip":"37404","country":"United States","geoPoint":{"lat":35.04563,"lon":-85.30968}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Memphis","state":"Tennessee","zip":"38119","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fort Worth","state":"Texas","zip":"76104","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Salt Lake City","state":"Utah","zip":"84106","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Richmond","state":"Virginia","zip":"23230","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kennewick","state":"Washington","zip":"99336","country":"United States","geoPoint":{"lat":46.21125,"lon":-119.13723}}]},"referencesModule":{"references":[{"pmid":"25371077","type":"DERIVED","citation":"Zinner RG, Obasaju CK, Spigel DR, Weaver RW, Beck JT, Waterhouse DM, Modiano MR, Hrinczenko B, Nikolinakos PG, Liu J, Koustenis AG, Winfree KB, Melemed SA, Guba SC, Ortuzar WI, Desaiah D, Treat JA, Govindan R, Ross HJ. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015 Jan;10(1):134-42. doi: 10.1097/JTO.0000000000000366."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.","accessCriteria":"A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.","url":"https://vivli.org/"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Completers included participants who died, participants with progressive disease and those who got randomized but didn't receive any treatment.","groups":[{"id":"FG000","title":"Pemetrexed + Carboplatin","description":"Induction therapy: pemetrexed 500 milligrams/square meter (mg/m²) given intravenously plus carboplatin area under the curve (AUC) 6 \\[maximum possible dose of 900 milligrams (mg)\\] intravenously infused over 30 minutes for four 21-day cycles.\n\nMaintenance therapy: pemetrexed 500 mg/m² given intravenously every 21 days until disease progression or treatment discontinuation."},{"id":"FG001","title":"Paclitaxel + Carboplatin + Bevacizumab","description":"Induction therapy: paclitaxel 200 mg/m² intravenously infused over 3 hours plus carboplatin AUC 6 (maximum possible dose of 900 mg) intravenously infused over 30 minutes plus bevacizumab 15 milligrams/kilogram (mg/kg) given intravenously for four 21-day cycles.\n\nMaintenance therapy: bevacizumab 15 mg/kg given intravenously every 21 days until disease progression or treatment discontinuation."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"182"},{"groupId":"FG001","numSubjects":"179"}]},{"type":"Received Any Amount of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"171"},{"groupId":"FG001","numSubjects":"166"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"181"},{"groupId":"FG001","numSubjects":"179"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized participants.","groups":[{"id":"BG000","title":"Pemetrexed + Carboplatin","description":"Induction therapy: pemetrexed 500 milligrams/square meter (mg/m²) given intravenously plus carboplatin area under the curve (AUC) 6 \\[maximum possible dose of 900 milligrams (mg)\\] intravenously infused over 30 minutes for four 21-day cycles.\n\nMaintenance therapy: pemetrexed 500 mg/m² given intravenously every 21 days until disease progression or treatment discontinuation."},{"id":"BG001","title":"Paclitaxel + Carboplatin + Bevacizumab","description":"Induction therapy: paclitaxel 200 mg/m² intravenously infused over 3 hours plus carboplatin AUC 6 (maximum possible dose of 900 mg) intravenously infused over 30 minutes plus bevacizumab 15 milligrams/kilogram (mg/kg) given intravenously for four 21-day cycles.\n\nMaintenance therapy: bevacizumab 15 mg/kg given intravenously every 21 days until disease progression or treatment discontinuation."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"182"},{"groupId":"BG001","value":"179"},{"groupId":"BG002","value":"361"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"64.8","spread":"9.62"},{"groupId":"BG001","value":"64.6","spread":"8.82"},{"groupId":"BG002","value":"64.7","spread":"9.22"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"77"},{"groupId":"BG001","value":"75"},{"groupId":"BG002","value":"152"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"105"},{"groupId":"BG001","value":"104"},{"groupId":"BG002","value":"209"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"9"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"178"},{"groupId":"BG001","value":"174"},{"groupId":"BG002","value":"352"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"31"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"165"},{"groupId":"BG001","value":"157"},{"groupId":"BG002","value":"322"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"182"},{"groupId":"BG001","value":"179"},{"groupId":"BG002","value":"361"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival Without Grade 4 Toxicity (G4PFS) as Measured by the Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0","description":"G4PFS was defined as the duration from the date of randomization to the earliest occurrence date of one of the following three events: Common Terminology Criteria (CTC) grade 4 adverse events (G4AEs), or progressive disease (PD) or death from any cause, whichever occurred earlier. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. PD is ≥20% increase in sum of longest diameter of target lesions or the appearance of new lesions. For participants who had no G4AEs, or PD, or death at the time of the data inclusion cutoff, PFS was censored at their last objective progression-free disease assessment prior to the cutoff date or the date of initiation of subsequent systemic anticancer therapy.","populationDescription":"All randomized participants. The number of participants censored was 30 for pemetrexed + carboplatin group and 35 for paclitaxel + carboplatin + bevacizumab group.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to measured progressive disease or treatment discontinuation up to 39.49 months","groups":[{"id":"OG000","title":"Pemetrexed + Carboplatin","description":"Induction therapy: pemetrexed 500 milligrams/square meter (mg/m²) given intravenously plus carboplatin area under the curve (AUC) 6 \\[maximum possible dose of 900 milligrams (mg)\\] intravenously infused over 30 minutes for four 21-day cycles.\n\nMaintenance therapy: pemetrexed 500 mg/m² given intravenously every 21 days until disease progression or treatment discontinuation."},{"id":"OG001","title":"Paclitaxel + Carboplatin + Bevacizumab","description":"Induction therapy: paclitaxel 200 mg/m² intravenously infused over 3 hours plus carboplatin AUC 6 (maximum possible dose of 900 mg) intravenously infused over 30 minutes plus bevacizumab 15 milligrams/kilogram (mg/kg) given intravenously for four 21-day cycles.\n\nMaintenance therapy: bevacizumab 15 mg/kg given intravenously every 21 days until disease progression or treatment discontinuation."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"179"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.91","lowerLimit":"2.73","upperLimit":"4.37"},{"groupId":"OG001","value":"2.86","lowerLimit":"2.20","upperLimit":"4.30"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.176","statisticalMethod":"Log Rank","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS)","description":"PFS was defined as the duration from the date of randomization to the date of progressive disease (PD) or death from any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. PD was ≥20% increase in sum of longest diameter of target lesions or the appearance of new lesions. For participants who had no PD or death at the time of the data inclusion cutoff, PFS was censored at their last objective progression-free disease assessment prior to the cutoff date or the date of initiation of subsequent systemic anticancer therapy.","populationDescription":"All randomized participants. The number of participants censored was 35 for pemetrexed + carboplatin group and 49 for paclitaxel + carboplatin + bevacizumab group.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to measured progressive disease up to 39.49 months","groups":[{"id":"OG000","title":"Pemetrexed + Carboplatin","description":"Induction therapy: pemetrexed 500 milligrams/square meter (mg/m²) given intravenously plus carboplatin area under the curve (AUC) 6 \\[maximum possible dose of 900 milligrams (mg)\\] intravenously infused over 30 minutes for four 21-day cycles.\n\nMaintenance therapy: pemetrexed 500 mg/m² given intravenously every 21 days until disease progression or treatment discontinuation."},{"id":"OG001","title":"Paclitaxel + Carboplatin + Bevacizumab","description":"Induction therapy: paclitaxel 200 mg/m² intravenously infused over 3 hours plus carboplatin AUC 6 (maximum possible dose of 900 mg) intravenously infused over 30 minutes plus bevacizumab 15 milligrams/kilogram (mg/kg) given intravenously for four 21-day cycles.\n\nMaintenance therapy: bevacizumab 15 mg/kg given intravenously every 21 days until disease progression or treatment discontinuation."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"179"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.44","lowerLimit":"4.21","upperLimit":"5.32"},{"groupId":"OG001","value":"5.45","lowerLimit":"5.03","upperLimit":"5.95"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.610","statisticalMethod":"Log Rank","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was defined as the duration from the date of randomization to the date of death from any cause. For participants who were alive at the time of the data inclusion cutoff, OS was censored at the last date the participant was known to be alive.","populationDescription":"All randomized participants. The number of participants censored was 52 for pemetrexed + carboplatin group and 56 for paclitaxel + carboplatin + bevacizumab group.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to date of death from any cause up to 39.49 months","groups":[{"id":"OG000","title":"Pemetrexed + Carboplatin","description":"Induction therapy: pemetrexed 500 milligrams/square meter (mg/m²) given intravenously plus carboplatin area under the curve (AUC) 6 \\[maximum possible dose of 900 milligrams (mg)\\] intravenously infused over 30 minutes for four 21-day cycles.\n\nMaintenance therapy: pemetrexed 500 mg/m² given intravenously every 21 days until disease progression or treatment discontinuation."},{"id":"OG001","title":"Paclitaxel + Carboplatin + Bevacizumab","description":"Induction therapy: paclitaxel 200 mg/m² intravenously infused over 3 hours plus carboplatin AUC 6 (maximum possible dose of 900 mg) intravenously infused over 30 minutes plus bevacizumab 15 milligrams/kilogram (mg/kg) given intravenously for four 21-day cycles.\n\nMaintenance therapy: bevacizumab 15 mg/kg given intravenously every 21 days until disease progression or treatment discontinuation."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"179"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.51","lowerLimit":"9.26","upperLimit":"11.96"},{"groupId":"OG001","value":"11.66","lowerLimit":"9.17","upperLimit":"14.32"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.615","statisticalMethod":"Log Rank","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Percentage of Participants With Complete Response or Partial Response (Overall Tumor Response Rate)","description":"Overall Response rate (ORR) was the percentage of participants with a confirmed complete response (CR) or partial response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. CR was the disappearance of all target and non-target lesions; PR was a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesions. ORR was calculated as a total number of participants with CR or PR from the start of study treatment until disease progression or recurrence divided by the total number of participants treated, then multiplied by 100.","populationDescription":"All randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline to date of objective progressive disease up to 39.49 months","groups":[{"id":"OG000","title":"Pemetrexed + Carboplatin","description":"Induction therapy: pemetrexed 500 milligrams/square meter (mg/m²) given intravenously plus carboplatin area under the curve (AUC) 6 \\[maximum possible dose of 900 milligrams (mg)\\] intravenously infused over 30 minutes for four 21-day cycles.\n\nMaintenance therapy: pemetrexed 500 mg/m² given intravenously every 21 days until disease progression or treatment discontinuation."},{"id":"OG001","title":"Paclitaxel + Carboplatin + Bevacizumab","description":"Induction therapy: paclitaxel 200 mg/m² intravenously infused over 3 hours plus carboplatin AUC 6 (maximum possible dose of 900 mg) intravenously infused over 30 minutes plus bevacizumab 15 milligrams/kilogram (mg/kg) given intravenously for four 21-day cycles.\n\nMaintenance therapy: bevacizumab 15 mg/kg given intravenously every 21 days until disease progression or treatment discontinuation."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"179"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.6","lowerLimit":"17.7","upperLimit":"30.5"},{"groupId":"OG001","value":"27.4","lowerLimit":"21.0","upperLimit":"34.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.414","statisticalMethod":"Pearson Chi-square Test","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Disease Control Rates Defined as Complete Response (CR), Partial Response (PR), and Stable Disease (SD)","description":"Disease control rate was the percentage of participants with a confirmed CR, PR or SD, as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. CR was the disappearance of all target and non-target lesions; PR was a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesion; SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Disease control rate was calculated as a total number of participants with CR or PR or SD divided by the total number of participants treated, then multiplied by 100.","populationDescription":"All randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline to date of objective progressive disease up to 39.49 months","groups":[{"id":"OG000","title":"Pemetrexed + Carboplatin","description":"Induction therapy: pemetrexed 500 milligrams/square meter (mg/m²) given intravenously plus carboplatin area under the curve (AUC) 6 \\[maximum possible dose of 900 milligrams (mg)\\] intravenously infused over 30 minutes for four 21-day cycles.\n\nMaintenance therapy: pemetrexed 500 mg/m² given intravenously every 21 days until disease progression or treatment discontinuation."},{"id":"OG001","title":"Paclitaxel + Carboplatin + Bevacizumab","description":"Induction therapy: paclitaxel 200 mg/m² intravenously infused over 3 hours plus carboplatin AUC 6 (maximum possible dose of 900 mg) intravenously infused over 30 minutes plus bevacizumab 15 milligrams/kilogram (mg/kg) given intravenously for four 21-day cycles.\n\nMaintenance therapy: bevacizumab 15 mg/kg given intravenously every 21 days until disease progression or treatment discontinuation."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"179"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.9","lowerLimit":"52.4","upperLimit":"67.1"},{"groupId":"OG001","value":"57.0","lowerLimit":"49.4","upperLimit":"64.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.575","statisticalMethod":"Pearson Chi-square Test","ciPctValue":"95"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Baseline to Follow-up (up to 9 years)","description":"Only those participants who received any amount of study drug were included in the safety analysis.","eventGroups":[{"id":"EG000","title":"Pemetrexed + Carboplatin","description":"Induction therapy: pemetrexed 500 milligrams/square meter (mg/m²) given intravenously plus carboplatin area under the curve (AUC) 6 \\[maximum possible dose of 900 milligrams (mg)\\] intravenously infused over 30 minutes for four 21-day cycles. Maintenance therapy: pemetrexed 500 mg/m² given intravenously every 21 days until disease progression or treatment discontinuation.","seriousNumAffected":76,"seriousNumAtRisk":171,"otherNumAffected":167,"otherNumAtRisk":171},{"id":"EG001","title":"Paclitaxel + Carboplatin + Bevacizumab","description":"Induction therapy: paclitaxel 200 mg/m² intravenously infused over 3 hours plus carboplatin AUC 6 (maximum possible dose of 900 mg) intravenously infused over 30 minutes plus bevacizumab 15 milligrams/kilogram (mg/ kg) given intravenously for four 21-day cycles. Maintenance therapy: bevacizumab 15 mg/kg given intravenously every 21 days until disease progression or treatment discontinuation.","seriousNumAffected":64,"seriousNumAtRisk":166,"otherNumAffected":160,"otherNumAtRisk":166}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":12,"numAtRisk":171},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":166}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":166}]},{"term":"Haemorrhagic anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":171},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":166}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":4,"numAtRisk":171},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":166}]},{"term":"Angina unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":166}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":13,"numAffected":3,"numAtRisk":166}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Cardiomyopathy acute","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":2,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Nodal arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Ventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Blindness","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":166}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":171},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":166}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":166}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":171},{"groupId":"EG001","numEvents":12,"numAffected":6,"numAtRisk":166}]},{"term":"Diverticulum intestinal haemorrhagic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Haematemesis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Large intestine perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":166}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":171},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":166}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Rectal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":171},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":166}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":171},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":166}]},{"term":"Catheter site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":166}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":5,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":166}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":171},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":166}]},{"term":"Hyperbilirubinaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":2,"numAtRisk":171},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":166}]},{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":166}]},{"term":"Device related sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":6,"numAffected":2,"numAtRisk":166}]},{"term":"Osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":15,"numAffected":1,"numAtRisk":166}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":14,"numAtRisk":171},{"groupId":"EG001","numEvents":13,"numAffected":6,"numAtRisk":166}]},{"term":"Pneumonia mycoplasmal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Psoas abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":15,"numAffected":1,"numAtRisk":166}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":166}]},{"term":"Cervical vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Clavicle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Pelvic fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":166}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Toxicity to various agents","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Troponin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":171},{"groupId":"EG001","numEvents":15,"numAffected":11,"numAtRisk":166}]},{"term":"Failure to thrive","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":166}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":166}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":171},{"groupId":"EG001","numEvents":5,"numAffected":2,"numAtRisk":166}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Hypovolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Lactic acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":166}]},{"term":"Bone lesion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":166}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Groin pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":166}]},{"term":"Hypertrophic osteoarthropathy","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":166}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":166}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Lung neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Malignant pleural effusion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Metastases to meninges","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":166}]},{"term":"Metastatic neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":166}]},{"term":"Neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":166}]},{"term":"Autonomic nervous system imbalance","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":4,"numAffected":1,"numAtRisk":166}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Depressed level of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":166}]},{"term":"Embolic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Lacunar infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":4,"numAffected":1,"numAtRisk":166}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":5,"numAffected":2,"numAtRisk":166}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":171},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":166}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Emotional distress","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":166}]},{"term":"Psychotic disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":166}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Nephrotic syndrome","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":166}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":171},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":166}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":166}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":40,"numAffected":4,"numAtRisk":171},{"groupId":"EG001","numEvents":8,"numAffected":2,"numAtRisk":166}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":6,"numAtRisk":171},{"groupId":"EG001","numEvents":10,"numAffected":4,"numAtRisk":166}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":166}]},{"term":"Hydropneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":166}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":171},{"groupId":"EG001","numEvents":10,"numAffected":3,"numAtRisk":166}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":166}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":8,"numAtRisk":171},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":166}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":171},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":166}]},{"term":"Stridor","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":3,"numAtRisk":171},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":166}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":166}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":166}]},{"term":"Haemorrhage","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":171},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":166}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":171},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":166}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":171},{"groupId":"EG001","numEvents":7,"numAffected":4,"numAtRisk":166}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":599,"numAffected":92,"numAtRisk":171},{"groupId":"EG001","numEvents":380,"numAffected":59,"numAtRisk":166}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":152,"numAffected":39,"numAtRisk":171},{"groupId":"EG001","numEvents":89,"numAffected":32,"numAtRisk":166}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":204,"numAffected":57,"numAtRisk":171},{"groupId":"EG001","numEvents":270,"numAffected":80,"numAtRisk":166}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":329,"numAffected":68,"numAtRisk":171},{"groupId":"EG001","numEvents":154,"numAffected":47,"numAtRisk":166}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":107,"numAffected":14,"numAtRisk":171},{"groupId":"EG001","numEvents":4,"numAffected":1,"numAtRisk":166}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":49,"numAffected":14,"numAtRisk":171},{"groupId":"EG001","numEvents":29,"numAffected":14,"numAtRisk":166}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":481,"numAffected":74,"numAtRisk":171},{"groupId":"EG001","numEvents":428,"numAffected":68,"numAtRisk":166}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":108,"numAffected":30,"numAtRisk":171},{"groupId":"EG001","numEvents":263,"numAffected":49,"numAtRisk":166}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":157,"numAffected":19,"numAtRisk":171},{"groupId":"EG001","numEvents":75,"numAffected":15,"numAtRisk":166}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":4,"numAtRisk":171},{"groupId":"EG001","numEvents":24,"numAffected":10,"numAtRisk":166}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":51,"numAffected":5,"numAtRisk":171},{"groupId":"EG001","numEvents":121,"numAffected":10,"numAtRisk":166}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":610,"numAffected":102,"numAtRisk":171},{"groupId":"EG001","numEvents":268,"numAffected":69,"numAtRisk":166}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":72,"numAffected":14,"numAtRisk":171},{"groupId":"EG001","numEvents":46,"numAffected":15,"numAtRisk":166}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":162,"numAffected":49,"numAtRisk":171},{"groupId":"EG001","numEvents":83,"numAffected":32,"numAtRisk":166}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":9,"numAtRisk":171},{"groupId":"EG001","numEvents":147,"numAffected":20,"numAtRisk":166}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":62,"numAffected":17,"numAtRisk":171},{"groupId":"EG001","numEvents":37,"numAffected":12,"numAtRisk":166}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":12,"numAtRisk":171},{"groupId":"EG001","numEvents":18,"numAffected":8,"numAtRisk":166}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1045,"numAffected":107,"numAtRisk":171},{"groupId":"EG001","numEvents":827,"numAffected":87,"numAtRisk":166}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":39,"numAffected":11,"numAtRisk":171},{"groupId":"EG001","numEvents":95,"numAffected":17,"numAtRisk":166}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":481,"numAffected":34,"numAtRisk":171},{"groupId":"EG001","numEvents":71,"numAffected":12,"numAtRisk":166}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":8,"numAtRisk":171},{"groupId":"EG001","numEvents":64,"numAffected":9,"numAtRisk":166}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":15,"numAtRisk":171},{"groupId":"EG001","numEvents":15,"numAffected":11,"numAtRisk":166}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":5,"numAtRisk":171},{"groupId":"EG001","numEvents":21,"numAffected":12,"numAtRisk":166}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":10,"numAtRisk":171},{"groupId":"EG001","numEvents":20,"numAffected":6,"numAtRisk":166}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":12,"numAtRisk":171},{"groupId":"EG001","numEvents":31,"numAffected":12,"numAtRisk":166}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":9,"numAtRisk":171},{"groupId":"EG001","numEvents":9,"numAffected":5,"numAtRisk":166}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":20,"numAtRisk":171},{"groupId":"EG001","numEvents":14,"numAffected":10,"numAtRisk":166}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":58,"numAffected":14,"numAtRisk":171},{"groupId":"EG001","numEvents":29,"numAffected":7,"numAtRisk":166}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":51,"numAffected":14,"numAtRisk":171},{"groupId":"EG001","numEvents":15,"numAffected":7,"numAtRisk":166}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":56,"numAffected":14,"numAtRisk":171},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":166}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":120,"numAffected":23,"numAtRisk":171},{"groupId":"EG001","numEvents":51,"numAffected":8,"numAtRisk":166}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":43,"numAffected":12,"numAtRisk":171},{"groupId":"EG001","numEvents":53,"numAffected":20,"numAtRisk":166}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":66,"numAffected":20,"numAtRisk":171},{"groupId":"EG001","numEvents":43,"numAffected":8,"numAtRisk":166}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":88,"numAffected":15,"numAtRisk":171},{"groupId":"EG001","numEvents":155,"numAffected":30,"numAtRisk":166}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":8,"numAtRisk":171},{"groupId":"EG001","numEvents":25,"numAffected":12,"numAtRisk":166}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":281,"numAffected":52,"numAtRisk":171},{"groupId":"EG001","numEvents":310,"numAffected":53,"numAtRisk":166}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":48,"numAffected":22,"numAtRisk":171},{"groupId":"EG001","numEvents":66,"numAffected":20,"numAtRisk":166}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":356,"numAffected":33,"numAtRisk":171},{"groupId":"EG001","numEvents":104,"numAffected":22,"numAtRisk":166}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":61,"numAffected":24,"numAtRisk":171},{"groupId":"EG001","numEvents":41,"numAffected":15,"numAtRisk":166}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":142,"numAffected":21,"numAtRisk":171},{"groupId":"EG001","numEvents":86,"numAffected":24,"numAtRisk":166}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":79,"numAffected":17,"numAtRisk":171},{"groupId":"EG001","numEvents":85,"numAffected":17,"numAtRisk":166}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":149,"numAffected":21,"numAtRisk":171},{"groupId":"EG001","numEvents":285,"numAffected":38,"numAtRisk":166}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":164,"numAffected":19,"numAtRisk":171},{"groupId":"EG001","numEvents":90,"numAffected":15,"numAtRisk":166}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":5,"numAtRisk":171},{"groupId":"EG001","numEvents":114,"numAffected":17,"numAtRisk":166}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":68,"numAffected":12,"numAtRisk":171},{"groupId":"EG001","numEvents":19,"numAffected":6,"numAtRisk":166}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":10,"numAtRisk":171},{"groupId":"EG001","numEvents":95,"numAffected":11,"numAtRisk":166}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":70,"numAffected":10,"numAtRisk":171},{"groupId":"EG001","numEvents":134,"numAffected":22,"numAtRisk":166}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":95,"numAffected":13,"numAtRisk":171},{"groupId":"EG001","numEvents":88,"numAffected":19,"numAtRisk":166}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":148,"numAffected":27,"numAtRisk":171},{"groupId":"EG001","numEvents":64,"numAffected":20,"numAtRisk":166}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":142,"numAffected":20,"numAtRisk":171},{"groupId":"EG001","numEvents":128,"numAffected":25,"numAtRisk":166}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":170,"numAffected":23,"numAtRisk":171},{"groupId":"EG001","numEvents":213,"numAffected":25,"numAtRisk":166}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":9,"numAtRisk":171},{"groupId":"EG001","numEvents":329,"numAffected":36,"numAtRisk":166}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":83,"numAffected":9,"numAtRisk":171},{"groupId":"EG001","numEvents":251,"numAffected":28,"numAtRisk":166}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":117,"numAffected":17,"numAtRisk":171},{"groupId":"EG001","numEvents":108,"numAffected":13,"numAtRisk":166}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":160,"numAffected":12,"numAtRisk":171},{"groupId":"EG001","numEvents":63,"numAffected":9,"numAtRisk":166}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":330,"numAffected":35,"numAtRisk":171},{"groupId":"EG001","numEvents":251,"numAffected":31,"numAtRisk":166}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":59,"numAffected":11,"numAtRisk":171},{"groupId":"EG001","numEvents":136,"numAffected":18,"numAtRisk":166}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":214,"numAffected":36,"numAtRisk":171},{"groupId":"EG001","numEvents":235,"numAffected":24,"numAtRisk":166}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":4,"numAtRisk":171},{"groupId":"EG001","numEvents":109,"numAffected":16,"numAtRisk":166}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":165,"numAffected":38,"numAtRisk":171},{"groupId":"EG001","numEvents":255,"numAffected":33,"numAtRisk":166}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":49,"numAffected":17,"numAtRisk":171},{"groupId":"EG001","numEvents":174,"numAffected":43,"numAtRisk":166}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":8,"numAtRisk":171},{"groupId":"EG001","numEvents":19,"numAffected":10,"numAtRisk":166}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":103,"numAffected":14,"numAtRisk":171},{"groupId":"EG001","numEvents":441,"numAffected":56,"numAtRisk":166}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":112,"numAffected":11,"numAtRisk":171},{"groupId":"EG001","numEvents":9,"numAffected":3,"numAtRisk":166}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":83,"numAffected":21,"numAtRisk":171},{"groupId":"EG001","numEvents":65,"numAffected":15,"numAtRisk":166}]},{"term":"Flushing","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":45,"numAffected":9,"numAtRisk":171},{"groupId":"EG001","numEvents":13,"numAffected":4,"numAtRisk":166}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":3,"numAtRisk":171},{"groupId":"EG001","numEvents":293,"numAffected":26,"numAtRisk":166}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":12,"numAtRisk":171},{"groupId":"EG001","numEvents":30,"numAffected":11,"numAtRisk":166}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","email":"ClinicalTrials.gov@lilly.com","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Puerto Rico"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D008175","term":"Lung Neoplasms"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068437","term":"Pemetrexed"},{"id":"D016190","term":"Carboplatin"},{"id":"D017239","term":"Paclitaxel"},{"id":"D000068258","term":"Bevacizumab"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"}]}},"hasResults":true}